JP2016521752A - Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法 - Google Patents

Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法 Download PDF

Info

Publication number
JP2016521752A
JP2016521752A JP2016519661A JP2016519661A JP2016521752A JP 2016521752 A JP2016521752 A JP 2016521752A JP 2016519661 A JP2016519661 A JP 2016519661A JP 2016519661 A JP2016519661 A JP 2016519661A JP 2016521752 A JP2016521752 A JP 2016521752A
Authority
JP
Japan
Prior art keywords
antibody
ihf
polypeptide
biofilm
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016519661A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016521752A5 (enExample
Inventor
スティーブン ディー． グッドマン，
スティーブン ディー． グッドマン，
ローレン オー． バカレッツ，
ローレン オー． バカレッツ，
アマル アメル，
アマル アメル，
Original Assignee
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
ユニバーシティ オブ サザン カリフォルニア
ユニバーシティ オブ サザン カリフォルニア
オハイオ・ステイト・イノベーション・ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル, リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル, ユニバーシティ オブ サザン カリフォルニア, ユニバーシティ オブ サザン カリフォルニア, オハイオ・ステイト・イノベーション・ファウンデーション filed Critical リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル
Publication of JP2016521752A publication Critical patent/JP2016521752A/ja
Publication of JP2016521752A5 publication Critical patent/JP2016521752A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0208—Specific bacteria not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1214—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Pseudomonadaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2016519661A 2013-06-13 2014-06-12 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法 Pending JP2016521752A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361834846P 2013-06-13 2013-06-13
US61/834,846 2013-06-13
PCT/US2014/042201 WO2014201305A1 (en) 2013-06-13 2014-06-12 Compositions and methods for the treatment of burkholderia infections

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2017109356A Division JP2017143841A (ja) 2013-06-13 2017-06-01 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2018187557A Division JP6832901B2 (ja) 2013-06-13 2018-10-02 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法

Publications (2)

Publication Number Publication Date
JP2016521752A true JP2016521752A (ja) 2016-07-25
JP2016521752A5 JP2016521752A5 (enExample) 2017-07-13

Family

ID=51177157

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2016519661A Pending JP2016521752A (ja) 2013-06-13 2014-06-12 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2017109356A Ceased JP2017143841A (ja) 2013-06-13 2017-06-01 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2018187557A Active JP6832901B2 (ja) 2013-06-13 2018-10-02 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2019223668A Withdrawn JP2020037595A (ja) 2013-06-13 2019-12-11 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2022088322A Pending JP2022116236A (ja) 2013-06-13 2022-05-31 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2023041844A Ceased JP2023072074A (ja) 2013-06-13 2023-03-16 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2024034820A Ceased JP2024060001A (ja) 2013-06-13 2024-03-07 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2025078757A Pending JP2025122007A (ja) 2013-06-13 2025-05-09 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法

Family Applications After (7)

Application Number Title Priority Date Filing Date
JP2017109356A Ceased JP2017143841A (ja) 2013-06-13 2017-06-01 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2018187557A Active JP6832901B2 (ja) 2013-06-13 2018-10-02 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2019223668A Withdrawn JP2020037595A (ja) 2013-06-13 2019-12-11 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2022088322A Pending JP2022116236A (ja) 2013-06-13 2022-05-31 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2023041844A Ceased JP2023072074A (ja) 2013-06-13 2023-03-16 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2024034820A Ceased JP2024060001A (ja) 2013-06-13 2024-03-07 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP2025078757A Pending JP2025122007A (ja) 2013-06-13 2025-05-09 Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法

Country Status (7)

Country Link
US (1) US20160175440A1 (enExample)
EP (1) EP3008088B1 (enExample)
JP (8) JP2016521752A (enExample)
AU (4) AU2014278037A1 (enExample)
CA (1) CA2915210A1 (enExample)
ES (1) ES2746971T3 (enExample)
WO (1) WO2014201305A1 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506221A (ja) * 2017-01-04 2020-02-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
JP2020513838A (ja) * 2017-01-04 2020-05-21 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
JP2022512580A (ja) * 2018-10-05 2022-02-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084373A1 (es) 2010-03-29 2013-05-15 Univ Southern California Composiciones y metodos para la eliminacion de biopeliculas
AU2011299025B2 (en) 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10624934B2 (en) 2014-03-06 2020-04-21 Research Institute At Nationwide Children's Hospital Prebiotic formulations
WO2015134808A2 (en) * 2014-03-06 2015-09-11 Research Institute At Nationwide Children's Hospital Probiotic formulations and methods for use
WO2016154491A1 (en) * 2015-03-25 2016-09-29 Trellis Bioscience, Llc Binding moieties for biofilm remediation
EP3328429B1 (en) 2015-07-31 2025-07-16 The Research Institute at Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
WO2017066719A2 (en) 2015-10-14 2017-04-20 Research Institute At Nationwide Children's Hospital Hu specific interfering agents
EP3595445B1 (en) 2017-03-15 2024-09-04 The Research Institute at Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2020072993A1 (en) 2018-10-05 2020-04-09 Research Institute At Nationwide Children's Hospital Hmgb1 protein derivatives for the removal of biofilms cross-reference to related application
EP3979830B1 (en) 2019-06-03 2025-11-26 Research Institute at Nationwide Children's Hospital Formulations for the treatment of neurodevelopmental deficiencies induced by necrotizing enterocolitis
WO2023228443A1 (ja) 2022-05-24 2023-11-30 株式会社オクト バイオフィルムを破壊するための溶液及びその製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123396A1 (en) * 2010-03-29 2011-10-06 University Of Southern California Compositions and methods for the removal of biofilms

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5202764B2 (ja) * 2009-06-03 2013-06-05 アルギファルマ エーエス 細菌における多剤耐性の克服に使用されるアルギネートオリゴマー
ES2739979T3 (es) * 2009-09-04 2020-02-05 Horizon Orphan Llc Uso de levofloxacino en aerosol para el tratamiento de la fibrosis quística
AU2011299025B2 (en) * 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011123396A1 (en) * 2010-03-29 2011-10-06 University Of Southern California Compositions and methods for the removal of biofilms

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEORGE AM, ET AL.: "Cystic fibrosis infections: treatment strategies and prospects", FEMS MICROBIOLOGY LETTERS, vol. 300, no. 2, JPN6018012317, 6 August 2009 (2009-08-06), pages 153 - 164, ISSN: 0003992784 *
GOODMAN SD, ET AL.: "Biofilms can be dispersed by focusing the immune system on a common family of bacterial nucleoid-ass", MUCOSAL IMMUNOLOGY, vol. 4, no. 6, JPN6018012316, 29 June 2011 (2011-06-29), pages 625 - 637, XP009155507, ISSN: 0003992783, DOI: 10.1038/mi.2011.27 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506221A (ja) * 2017-01-04 2020-02-27 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
JP2020513838A (ja) * 2017-01-04 2020-05-21 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
JP2022171777A (ja) * 2017-01-04 2022-11-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
JP2023033394A (ja) * 2017-01-04 2023-03-10 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル バイオフィルム関連障害の処置のための抗体断片
JP7514621B2 (ja) 2017-01-04 2024-07-11 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
US12419944B2 (en) 2017-01-04 2025-09-23 Research Institute At Nationwide Children's Hospital DNABII vaccines and antibodies with enhanced activity
JP2022512580A (ja) * 2018-10-05 2022-02-07 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
JP7541513B2 (ja) 2018-10-05 2024-08-28 リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル 細菌バイオフィルムの酵素的破壊のための組成物および方法
US12209118B2 (en) 2019-07-08 2025-01-28 Research Institute At Nationwide Children's Hospital Antibody compositions for disrupting biofilms

Also Published As

Publication number Publication date
JP2020037595A (ja) 2020-03-12
AU2023202534A1 (en) 2023-05-18
CA2915210A1 (en) 2014-12-18
JP2024060001A (ja) 2024-05-01
JP2023072074A (ja) 2023-05-23
JP2022116236A (ja) 2022-08-09
JP2017143841A (ja) 2017-08-24
US20160175440A1 (en) 2016-06-23
HK1222398A1 (en) 2017-06-30
EP3008088A1 (en) 2016-04-20
JP6832901B2 (ja) 2021-02-24
JP2025122007A (ja) 2025-08-20
JP2019010122A (ja) 2019-01-24
AU2020203092A1 (en) 2020-05-28
WO2014201305A1 (en) 2014-12-18
ES2746971T3 (es) 2020-03-09
AU2018202762A1 (en) 2018-05-10
AU2014278037A1 (en) 2016-01-07
AU2018202762B2 (en) 2020-07-02
EP3008088B1 (en) 2019-08-21
AU2018202762C1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
JP6832901B2 (ja) Ｂｕｒｋｈｏｌｄｅｒｉａ感染の処置のための組成物および方法
JP6351972B2 (ja) バイオフィルムの除去のための組成物および方法
JP7593979B2 (ja) バイオフィルムの除去のためのペプチドおよび抗体
JP7627255B2 (ja) バイオフィルムを破壊するための抗体組成物
JP7514621B2 (ja) Ｄｎａｂｉｉワクチンおよび強化された活性を有する抗体
JP7661008B2 (ja) バイオフィルム関連障害の処置のための抗体断片
JP2021529180A (ja) Ｅｐｓを媒介するための組成物および方法
JP2024105533A (ja) 細菌バイオフィルムの酵素的破壊のための組成物および方法
CN116096239B (zh) 治疗和预防生物膜的联合疗法
RU2851685C2 (ru) Композиции антител для разрушения биопленок
JP2025537168A (ja) バイオフィルムおよび好中球細胞外トラップ形成を処置するための組成物および方法
HK1222398B (en) Compositions and methods for the treatment of burkholderia infections

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160212

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181002

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190307